**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 71742

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss**

Zhang YL *et al*. JQBD improves metabolic bone disorder

Ya-Li Zhang, Qian Chen, Lie Zheng, Zi-Wei Zhang, Yu-Jun Chen, Yan-Cheng Dai, Zhi-Peng Tang

**Ya-Li Zhang, Qian Chen, Zi-Wei Zhang, Yu-Jun Chen, Zhi-Peng Tang,** Institute of Digestive Diseases, LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

**Lie Zheng,** Department of Gastroenterology, Traditional Chinese Medicine Hospital of Shaanxi Province, Xi’an 710003, Shaanxi Province, China

**Yan-Cheng Dai,** Department of Gastroenterology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China

**Author contributions:** Zhang YL and Chen Q contributed equally to this work, and both performed the majority of research; Dai YC, Zheng L, Zhang ZW, and Chen YJ performed the research and analyzed the data; Tang ZP designed and coordinated the research; Zhang YL and Chen Q wrote and revised the paper; all authors read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 81704009 and No. 81873253; the Key Clinical Specialty Construction Project supported by Hongkou District Health Committee, No. HKZK2020A01; and the Sixth Round of Academic Experience Successors Training Project for Veteran Practitioner of Traditional Chinese Medicine (The Document of the State Administration of Traditional Chinese Medicine 2017), No. 29.

**Corresponding author: Zhi-Peng Tang, MD, PhD, Chief Doctor, Professor,** Institute of Digestive Diseases, LongHua Hospital, Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Shanghai 200032, China. zhipengtang@sohu.com

**Received:** September 20, 2021

**Revised:** January 17, 2022

**Accepted:** February 27, 2022

**Published online:** April 7, 2022

**Abstract**

BACKGROUND

Bone loss and osteoporosis are commonly described as extra-intestinal manifestations of inflammatory bowel disease (IBD). Jianpi Qingchang Bushen decoction (JQBD) is a prescription used in clinical practice. However, further studies are needed to determine whether JQBD regulates the receptor activator of nuclear factor kappa B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG) pathways and could play a role in treating IBD-induced bone loss.

AIM

To evaluate the therapeutic effect of JQBD in IBD-induced bone loss and explore the underlying mechanisms.

METHODS

An IBD-induced bone loss model was constructed by feeding 12 6-to-8-wk-old interleukin-10 (IL-10)-knockout mice with piroxicam for 10 d. The mice were randomly divided into model and JQBD groups. We used wild-type mice as a control. The JQBD group was administered the JQBD suspension for 2 wk by gavage, while the control and model groups were given normal saline at the corresponding time points. All mice were killed after the intervention. The effect of JQBD on body weight, disease activity index (DAI), and colon length was analyzed. Histopathological examination, colon ultrastructure observation, and micro-computed tomographic scanning of the lumbar vertebrae were performed. The gene expression of NF-κB, tumor necrosis factor-α (TNF-α), IL-1β, IL-6, and IL-8 in the colon was evaluated by real-time polymerase chain reaction. Colon samples were assessed by Western blot for the expression of RANKL, OPG, RANK, and NF-κB proteins.

RESULTS

The model group lost body weight, had a shorter colon, and showed a dramatic increase in DAI score, whereas JQBD had protective and therapeutic effects. Treatment with JQBD significantly improved inflammatory cell infiltration and reduced crypt abscess and ulcer formation. Three-dimensional imaging of the vertebral centrum in the model group revealed a lower bone mass, loose trabeculae, and “rod-shaped” changes in the structure compared to the control group and JQBD groups. The bone volume/total volume ratio and bone mineral density were significantly lower in the model group than in the control group. JQBD intervention downregulated the NF-κB, TNF-α, IL-1β, IL-6, and IL-8 mRNA expression levels. The RANKL and OPG protein levels were also improved.

CONCLUSION

JQBD reduces inflammation of the colonic mucosa and inhibits activation of the RANK/RANKL/OPG signaling pathway, thereby reducing osteoclast activation and bone resorption and improving bone metabolism.

**Key Words:** Inflammatory bowel disease; Osteoporosis; Jianpi Qingchang Bushen decoction; Inflammation; Bone metabolism

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang YL, Chen Q, Zheng L, Zhang ZW, Chen YJ, Dai YC, Tang ZP. Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss. *World J Gastroenterol* 2022; 28(13): 1315-1328

**URL:** https://www.wjgnet.com/1007-9327/full/v28/i13/1315.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v28.i13.1315

**Core Tip:** Bone loss and osteoporosis are commonly described as extra-intestinal manifestations of inflammatory bowel disease (IBD). Jianpi Qingchang Bushen decoction (JQBD) is a prescription used in clinical practice. This study aimed to evaluate the therapeutic effect of JQBD in IBD-induced bone loss and explore the underlying mechanisms. An IBD-induced bone loss model was constructed by feeding interleukin-10-knockout mice with piroxicam. JQBD reduced inflammation of the colonic mucosa and inhibited activation of the receptor activator of nuclear factor kappa B (NF-κB)/receptor activator of NF-κB ligand/osteoprotegerin signaling pathway, thereby reducing osteoclast activation and bone resorption and improving bone metabolism.

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a chronic, relapsing immune-mediated inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC)[1,2]. Its main clinical manifestations are diarrhea, abdominal pain, bloody stool, and various degrees of systemic symptoms[3,4]. Nearly 50% of IBD patients show at least one kind of extra-intestinal symptom during their lifetime, among which musculoskeletal damage is the most common[5-7]. In recent years, increasing attention has been paid to the study of osteopenia and osteoporosis caused by IBD. Osteoporosis is a systemic bone disease characterized by low bone mass and the destruction of bone microstructure. It increases bone fragility, making it prone to fractures. Osteoporosis is one of the more common extraintestinal manifestations in IBD patients[8]. Studies have shown that the risk of osteoporosis is significantly higher in IBD patients than in healthy controls[9,10], exposing them to a higher risk of fracture. The risk of fracture in IBD patients is 40% higher than that in healthy controls, seriously affecting their quality of life[11]. The search for a suitable treatment to reduce pain and the economic burden has become a priority of international medical and social establishments.

The pathogenesis of osteoporosis in IBD patients has not been fully elucidated. Many factors affect bone metabolism. Recent studies have shown that intestinal inflammation is one of the most important factors leading to osteoporosis in IBD patients. Inflammation is involved in the pathophysiological process of bone loss in patients with IBD[12-14]. Therefore, controlling intestinal inflammation could help to prevent the occurrence and progression of osteoporosis. The receptor activator of nuclear factor kappa B (NF-κB; RANK), its ligand (receptor activator of NF-κB ligand, RANKL), and the soluble decoy receptor osteoprotegerin (OPG) orchestrate resorption of osteoclastic bone and play a key role in the common pathogenic pathway between gut inflammation and bone loss[15]. RANK/RANKL/OPG signaling is a key regulator of osteoclast biology and bone metabolism and an important pathway regulating osteoclast differentiation[16-18]. Stanisławowski *et al*[19] reported that patients with UC have higher local expression of serum OPG mRNA and protein than healthy participants[19]. Krela-Kaźmierczak *et al*[20] reported an increase in the OPG/RANKL ratio in CD patients[20]. According to a recent study, elevated osteocyte tumor necrosis factor (TNF)-α, interleukin (IL)-6, RANKL, and OPG correspond to higher osteoclast surfaces and a lower bone formation rate in an IBD model induced with dextran sodium sulfate[21]. No effective preventive or treatment modality exists for osteoporosis in IBD patients. A great deal of interest has been generated to evaluate the mechanism by which natural products exert their beneficial effects in the gastrointestinal tract[22]. Traditional Chinese medicine (TCM) has good effects on IBD patients with osteoporosis. Spleen and kidney insufficiencies and dampness-heat are important components of IBD-associated osteoporosis pathogenesis. Treatment is aimed at invigorating the spleen, clearing the intestine, and tonifying the kidney. Thus, Jianpi Qingchang Bushen decoction (JQBD) was established under the guidance of TCM theory. JQBD is a prescription developed by our team to treat IBD patients with osteoporosis. Our previous study reported that JQBD-medicated serum promotes osteoclast apoptosis by downregulating Bcl-2 and upregulating the expression of the Bax protein[23]. According to TCM theory, the kidney stores the essence and this can be transformed into the bone marrow to nourish the bones and strengthen the skeleton. Thus, a kidney deficiency can cause osteoporosis. Tonifying the kidneys regulates bone metabolism to alleviate osteoporosis. Modern pharmacological studies have confirmed that *Psoralea corylifolia* Linn, *Alpinia oxyphylla* Miq, and their extracts improve bone metabolism to prevent bone loss and are commonly used to treat osteoporosis[24-27].

In this study, the potential pharmacodynamic mechanism of JQBD for treating IBD-induced osteoporosis was studied *in vivo* for the first time. An IBD-induced osteoporosis model was constructed by treating interleukin (IL)-10-knockout mice with piroxicam. JQBD was given as an intervention, and its effects on the inflammatory response and bone metabolism were observed to provide a theoretical basis for the clinical prevention and treatment of osteoporosis in IBD patients.

**MATERIALS AND METHODS**

***TCM preparation and identification of the phytochemicals***

JQBD was prepared by the TCM pharmacy of Longhua Hospital, Shanghai University of TCM. It was composed of eight herbal species, including *Astragalus mongholicus* Bunge 30 g, *Codonopsis pilosula* (Franch.) Nannf. 15 g, *Alpinia oxyphylla* Miq. 12 g, *Cullen corylifolium* (L.) Medik. 9 g, *Portulaca oleracea* L. 30 g, *Sanguisorba officinalis* L. 15 g, *Aucklandia costus* Falc. 6 g, and *Glycyrrhiza glabra* L. 6 g. The components were soaked, boiled twice, filtered, concentrated, freeze-dried into a powder, and stored at −20 °C. Ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF/MS) was used to analyze the samples and identify 44 phytochemicals in JQBD. The MS chromatograms of the JQBD negative and positive ion modes are shown in Supplementary Figure 1. The chemical information of the identified phytochemicals is shown in Supplementary Table 1. Quality control measures were performed according to the guidelines of the Chinese State Food and Drug Administration.

***Animal model and drug intervention***

Six IL-10-knockout C57BL/6 mice were produced by the Shanghai Nanfang Research Center for Model Organisms (SNRCMO; Shanghai, China) and were maintained and bred in a specific-pathogen-free animal room at 23 ± 3 °C, 35%–45% relative humidity, and a 12 h/12 h light/dark regime at the Laboratory Animal Center of the Shanghai University of Traditional Chinese Medicine. Food and water were provided *ad libitum*. The Animal Ethics Committee of the Shanghai University of Traditional Chinese Medicine approved this study (PZSHUTCM191108004).

The IL-10-knockout mice were bred, and 70 F6-generation mice underwent gene detection using tail tip samples. IL-10 knockout was detected in 30 of these mice. We used wild-type mice as controls, which were the progeny of IL-10 +/- mating and bred at the same facility. The gene detection results are shown in Figure 1. The IBD-induced osteoporosis model was constructed by feeding the IL-10-knockout mice 200 ppm piroxicam for 10 d[28]. The mice were randomly divided into IL-10-knockout controls (model group) and IL-10-knockout mice with JQBD intervention (JQBD group). Six mice were included in each group (three males and three females). The JQBD group was administered 16.5 g/kg/d of the JQBD suspension by gavage, while the control and model groups were given the same volumes of normal saline at the corresponding time points. The intervention was conducted for 14 consecutive days. All mice were killed after the intervention, and blood samples and colon and bone tissues were harvested.

***Daily record of observational parameters***

The mental state, coat color, activity, body weight, diet, fecal traits, occult blood, and gross bloody stool were observed and recorded daily from the beginning of modeling. The disease activity index (DAI) score was used to evaluate colitis severity in the mice daily following the grading scheme presented in Table 1[29].

***Measurement of colon length and colon histopathological examination***

Dead mice were dissected to isolate the colon. The colons were placed on filter paper, and their length was measured with a ruler.

The colon samples were fixed in 4% paraformaldehyde solution, dehydrated, paraffin-embedded, sliced, and stained with hematoxylin and eosin (HE).

***Ultrastructural observation of the colon***

Part of each colon was fixed in 2.5% glutaraldehyde within 1 min, dehydrated, embedded, sliced, and stained with 3% uranium acetate and lead citrate. The colon ultrastructure was observed by transmission electron microscopy (TEM).

***Specimen preparation and micro-computed tomography***

After the mice were killed, the intact lumbar vertebrae were separated, and the residual soft tissue was removed. The bone tissue was fixed in a 75% ethanol solution pending the experiment. All specimen assessments were performed on the lumbar vertebra by μ-CT80 micro-computed tomography (CT) (SCANCO Medical AG, Bassersdorf, Switzerland). The scanning resolution was 18 μm *per* layer, followed by three-dimensional (3D) reconstruction. The morphometric analysis included bone volume/total volume (BV/TV) ratio, trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), connectivity-density (Conn-Dens), and bone mineral density (BMD).

***Real-time polymerase chain reaction detection of NF-κB, TNF-α, IL-1β, IL-6, and IL-8 mRNA expression levels***

Total RNA was extracted from the colon tissues with TRIzol, and the RNA concentration was determined. cDNA was reverse transcribed following the Takara kit instructions and was detected on the ABI StepOne Plus real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) instrument. The primers were designed and synthesized by Shanghai ShineGene Molecular Biotechnology Co., Ltd. (Shanghai, China) (Table 2) and verified using the BLAST program. A 20-μL RT-qPCR reaction system was configured, and the reaction amplification was carried out following the kit instructions. β-actin was used as the internal reference, fold-change was estimated by the 2-△△Ct method, and the mRNA expression level was compared between the groups. The assay was repeated three times.

***Detecting the effect of JQBD on RANKL, OPG, RANK, and NF-κB protein expression in colon tissue by Western blot***

We added 1 mL of RIPA Lysis Buffer and 10 μL of a protease inhibitor mixture to a homogenization tube and precooled it on ice; 50 μg of colon tissue was weighed and homogenized repeatedly in the tubes six times until no obvious tissue was seen in the homogenate. The homogenate was centrifuged (Eppendorf 5417R, Eppendorf) at 4 °C and 15000 × *g* for 15 min, and the supernatant was placed in another centrifugation tube. A small volume of the supernatant was taken, and the protein concentration was determined by the bicinchoninic acid method. Samples of 30 μg were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a membrane, and sealed. TBST-diluted RANKL, OPG, RANK, and NF-κB antibodies (1:1000) were added, and the membrane was incubated overnight at 4 °C. After the incubation, the membrane was washed and incubated for 1 h with gentle shaking at room temperature with fluorescence-labeled secondary antibody diluted 1:3000. TBST was used to rinse the membranes. An enhanced chemiluminescence kit (reagents A and B were mixed at equal volumes) was placed on the surface of the polyvinylidene fluoride (PVDF) membrane and incubated in the dark at room temperature for 1 min. The PVDF membrane was placed on the operating table of a Western blot imager, and a strip image was acquired. The gray values of the bands were analyzed using ImageJ analysis software.

***Statistical analysis***

Statistical analyses were performed using GraphPad Prism, version 8.0 software (GraphPad Software Inc., La Jolla, CA, United States). Data are expressed as the mean ± SD. Differences between groups were assessed by one-way analysis of variance. A *P* value < 0.05 was considered significant.

**RESULTS**

***General condition of the mice***

The control mice showed a flexible response, agile movement, glossy fur, pink paws, active foraging, normal water intake, and mostly globular feces that were negative for occult blood. The mice in the model group were lazy, with a reduced appetite, dirty and sparsely erected fur, white paws, soft feces, and perianal body hair stained with loose stools. Some had bloody stools, occasional anal peeling, perianal blood, feces strongly positive for occult blood, and decreased body weight. The JQBD group mice displayed a better mental status and they had glossy hair, only slightly white paws, feces not as soft, only occasional bloody stools, lower positive occult blood rate, and less lost weight than the model group (Figure 2).

***Weight change and DAI scores***

The weights of the mice in the model and JQBD groups on day 10 of the experiment were significantly lower *(P* < 0.05) than that of the control group. The weight in the JQBD group was higher than that in the model group (*P* < 0.05). The weight in all groups on day 14 was higher than that at the start of the experiment, but the weight increase in the model and JQBD groups was less evident than that in the control group (*P* < 0.05). The weight of the model group was significantly lower than that of the other two groups (*P* < 0.05). Higher DAI scores were observed in the model and JQBD groups. The DAI score of mice in the model group was higher than that of mice in the control group (*P* < 0.05), which decreased significantly in response to JQBD treatment on day 14 (*P* < 0.05) (Figure 3).

***Morphological changes in the colonic mucosa***

The colon wall in the control group was smooth, red, and resilient. In the model group, it was thickened, stiff, hyperemic, edematous, and erosive, with some irregular ulcers and a brittle texture. The colonic mucosa hyperemia and edema in the JQBD group were less severe than those in the model group with significantly reduced ulcer formation. The colon in the model group was significantly shorter than that in the control (*P* < 0.001) and the JQBD (*P* < 0.05) groups.

***Histological evaluation of the colonic mucosa***

The colonic mucosal epithelium in the control group was intact and continuous, the glands were orderly arranged, the goblet cells were visible, the blood vessels and fibrous interstitium in the lamina propria and muscle layer were normal, and inflammatory cell infiltration was rarely observed. Necrosis, erosion, disordered gland arrangement, different degrees of inflammatory cell infiltration, a reduced number of goblet cells, and ulcer formation were observed in the colonic mucosa of mice in the model group, suggesting successful IBD modeling in these mice. JQBD provided partial protection to the mucosa, so it was less damaged, showing mild to moderate hyperemia and edema. Lower inflammatory cell infiltration and ulcer formation rates were noted, and the glands were arranged in an orderly manner (Figure 4).

***Bone metabolic parameters on micro-computed tomography***

The 3D imaging of the vertebral centrum in the model group revealed a lower bone mass, loose trabeculae, and “rod-shaped” changes in the structure compared to the control group. Treatment with JQBD resulted in a higher bone mass, tighter trabecular bone gaps, and higher connectivity than those in the model group. The quantitative micro-CT results showed that the BV/TV ratio and BMD decreased in the model group. The Conn-Dens and Tb.Th were similar in the normal and model groups. Although BV/TV and BMD were significantly lower in the model group than in the control group, these values were similar in the JQBD, control, and model groups (Figure 5).

***Structural changes in the colonic epithelial cells as observed by TEM***

The TEM images illustrated intact colon cells in the control group, with no increase in intercellular space. The endoplasmic reticulum had a reticular structure and was bundled, the cavity was not expanded, many ribosomes were attached to it, and numerous mitochondria were observed. In the model group, the organelles were significantly swollen and the endoplasmic reticulum cavity was significantly expanded, attaining different shapes and sizes, with many vacuoles. Some of the organelles fused into clusters. A microvillar structure was partially observed in the JQBD group. The mitochondria were slightly swollen, the number of epithelial cells increased, and the cell structure was more intact than in the model group. The endoplasmic reticulum cavity was slightly expanded (Figure 4).

***Effect of JQBD on NF-κB, TNF-α, IL-1β, IL-6, and IL-8 gene expression***

The expression of the five genes was verified by RT-qPCR. The mRNA expression levels of NF-κB, TNF-α, IL-1β, IL-6, and IL-8 were significantly upregulated in the colon of the model group compared to the control group. JQBD intervention downregulated the mRNA expression levels of these genes, suggesting that JQBD improved the mucosal inflammatory response (Figure 6).

***Effect of JQBD on RANKL, OPG, RANK, and NF-κB protein expression***

The RANKL, OPG, RANK, and NF-κB protein levels were measured by Western blot. RANKL and OPG protein expression was significantly upregulated in the model group colon and was markedly downregulated following JQBD intervention. Although the RANK and NF-κB protein expression levels were significantly higher in the model group than in the control group, they were similar between the model and JQBD groups. Taken together, these data indicate that JQBD improved the mucosal inflammatory response and restrained the RANK/RANKL/OPG signaling pathway during the development of bone loss in IBD (Figure 7).

**DISCUSSION**

IBD is a chronic, non-specific, intestinal inflammatory disease with unclear etiology and common digestive system clinical presentation. The disease is protracted and difficult to cure, and the symptoms easily recur. IBD affects multiple systems, including the bones and calcium deposits. Studies have shown that IBD patients have a lower bone mass than healthy people[30-33]. The risk of osteoporosis and subsequent fractures is significantly higher in IBD patients[34,35], and it is the main cause of mobility problems and decreased quality of life in these patients[36]. Osteoporosis is a common and easily overlooked extra-intestinal manifestation in IBD patients. Early diagnosis and prevention of osteoporosis in IBD patients are very important. Therefore, we explored the possible pathogenesis of IBD-induced osteoporosis and evaluated the effectiveness of a promising drug in the present study. We propose that JQBD may have a protective effect against IBD-induced osteoporosis through the RANK/RANKL/OPG signaling pathway.

We established a bone loss IBD model in IL-10-knockout mice by peroral administration of piroxicam. IL-10-knockout mice are commonly used as an animal model to study IBD[37,38]. When exposed to non-steroidal anti-inflammatory drugs, such as piroxicam, these animals rapidly develop colitis that persists for a long time[39,40]. Holgersen *et al*[15] reported that they orally fed IL-10 knockout mice piroxicam for 12 d before the bone loss and trabecular bone structural changes occurred[15]. We report similar results in IL-10-knockout mice following 10 d of oral piroxicam administration. Our micro-CT data show that the BV/TV ratio and BMD were significantly lower in the model mice than in the controls. The 3D simulation map suggested that bone mass was significantly lower in the model group than in the control group and that the trabecular bone structure was lost, with visible fractures and destruction of the bone microstructure. The model group exhibited bone loss and significant colitis, similar to another report[41]. Our results preliminarily confirm the abnormal bone metabolism in the model group, suggesting successful modeling.

Our data show that the JQBD was protective against IBD-induced bone loss by inhibiting inflammation. Evidence shows that intestinal inflammation is involved in the pathophysiology of osteoporosis in IBD[42-44]. Expression of NF-κB, TNF-α, IL-1β, IL-6, and IL-8 mRNA in colonic tissue from the model group increased significantly, confirming that pro-inflammatory cytokines are involved in the occurrence of experimental colitis in piroxicam-induced IL-10-knockout mice with IBD. The administration of the JQBD reduced the levels of pro-inflammatory cytokines and decreased colonic inflammation. Several studies have evaluated the pathophysiology of IBD and its association with osteoporosis. Bone loss was initially attributed to the use of drugs, such as corticosteroids. However, it was later found that BMD decreases in IBD patients even without drug treatment, suggesting that IBD might be involved in the pathophysiology of bone loss, and chronic inflammation is the primary determinant[45-47].

We evaluated the curative effects of JQBD on the bone-loss IBD model mice and confirmed that the RANK/RANKL/OPG signaling pathway was involved in the process. The RANKL, OPG, RANK, and NF-κB protein levels increased significantly in colon tissue from the model group. Their expression levels were downregulated after JQBD intervention, suggesting that JQBD inhibits activation of the RANK/RANKL/OPG signaling pathway. Several pro-inflammatory cytokines, including IL-1β, TNF-α, IL-6, and IL-8 increase in IBD and have been shown to stimulate osteoclast differentiation[48]. Studies have suggested that the abnormal intestinal tract immune response in IBD leads to injury and inflammation of the intestinal mucosa, activation of the RANK /RANKL/OPG signaling pathway, changes in the bone conversion rate, osteoclast activation, and bone loss, leading to IBD-induced osteoporosis[21,49,50]. These results highlight the interactions between inflammation and the RANK/RANKL/OPG signaling pathway during the development of osteoporosis in IBD. JQBD reduced inflammation of the colonic mucosa and inhibited activation of the RANK/RANKL/OPG signaling pathway (Figure 8). Taken together, our present study data demonstrate that the JQBD improved IBD-induced osteoporosis *via* the RANK/RANKL/OPG signaling pathway.

This study primarily focused on the mechanism by which JQBD regulates the RANK/RANKL/OPG signaling pathway and improves IBD-induced osteoporosis. Our investigation has only preliminarily discussed the topic at the animal level and had several limitations. First, we considered using future emerging methods, such as systems pharmacology, to systematically explore the potential efficacy of JQBD in the treatment of IBD-induced osteoporosis. Such a study would include related experimental verification at the cell and animal levels. Second, the basic mechanism behind IBD-induced osteoporosis needs to be further explored. We will perform long-term observations in future experiments by extending the experimental period to 1 or 2 mo. We will also investigate the activation of the RANK/RANKL/OPG signaling pathway in bone tissues. Third, changes in intestinal microecology play an important role in the healing of the mucosa. Some studies have reported that an increase in the intestinal microbial bifidobacteria promotes healing of the colonic mucosa, increases the IL-10 level, and reduces the IL-6 and TNF-α levels[51,52]. The intestinal flora was not determined in this study. Thus, whether JQBD regulates intestinal microecology is worthy of further study.

**CONCLUSION**

JQBD plays a role in treating IBD-related bone metabolic abnormalities by inhibiting colonic mucosal inflammation, promoting mucosal healing, and inhibiting activation of the RANK/RANKL/OPG signaling pathway, osteoclast formation, and bone resorption.

**ARTICLE HIGHLIGHTS**

***Research background***

In recent years, increasing attention has been paid to the study of osteopenia and osteoporosis caused by inflammatory bowel disease (IBD). Osteoporosis is one of the more common extra-intestinal manifestations in IBD patients. No effective preventive or treatment modality exists for osteoporosis in IBD patients. Therefore, we explored the possible pathogenesis of IBD-induced osteoporosis and evaluated the effectiveness of a promising drug in the present study.

***Research motivation***

Jianpi Qingchang Bushen decoction (JQBD) is a prescription developed by our team to treat IBD patients with osteoporosis. In this study, the potential pharmacodynamic mechanism of JQBD for treating IBD-induced osteoporosis was studied *in vivo*.

***Research objectives***

The effects of JQBD on the inflammatory response and bone metabolism were observed to provide a theoretical basis for the clinical prevention and treatment of osteoporosis in IBD patients.

***Research methods***

An IBD-induced osteoporosis model was constructed by treating interleukin-10-knockout mice with piroxicam. JQBD was given as an intervention, and its effect on the inflammatory response and bone metabolism was observed.

***Research results***

Our data show that JQBD was protective against IBD-induced bone loss by inhibiting inflammation. The receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL), osteoprotegerin (OPG), receptor activator of NF-κB (RANK), and NF-κB protein levels increased significantly in colon tissue from the model group. Their expression levels were downregulated after JQBD intervention.

***Research conclusions***

We evaluated the curative effects of JQBD on the bone-loss IBD model mice and confirmed that the RANK/RANKL/OPG signaling pathway is involved in the process.

***Research perspectives***

This study primarily focused on the mechanism by which JQBD regulates the RANK/RANKL/OPG signaling pathway and improves IBD-induced osteoporosis.

**REFERENCES**

1 **Olpin JD**, Sjoberg BP, Stilwill SE, Jensen LE, Rezvani M, Shaaban AM. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. *Radiographics* 2017; **37**: 1135-1160 [PMID: 28548906 DOI: 10.1148/rg.2017160121]

2 **Shao BZ**, Wang SL, Pan P, Yao J, Wu K, Li ZS, Bai Y, Linghu EQ. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation. *Inflammation* 2019; **42**: 1147-1159 [PMID: 30937839 DOI: 10.1007/s10753-019-01008-y]

3 **Sairenji T**, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. *Prim Care* 2017; **44**: 673-692 [PMID: 29132528 DOI: 10.1016/j.pop.2017.07.010]

4 **Malik TA**. Inflammatory Bowel Disease: Historical Perspective, Epidemiology, and Risk Factors. *Surg Clin North Am* 2015; **95**: 1105-1122, v [PMID: 26596917 DOI: 10.1016/j.suc.2015.07.006]

5 **Greuter T**, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. *Expert Rev Gastroenterol Hepatol* 2019; **13**: 307-317 [PMID: 30791773 DOI: 10.1080/17474124.2019.1574569]

6 **Garber A**, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. *Curr Gastroenterol Rep* 2019; **21**: 31 [PMID: 31098819 DOI: 10.1007/s11894-019-0698-1]

7 **Kim YS**, Lee J. [Musculoskeletal Manifestation in Inflammatory Bowel Disease]. *Korean J Gastroenterol* 2019; **73**: 276-284 [PMID: 31132834 DOI: 10.4166/kjg.2019.73.5.276]

8 **Pellicano R**, Ribaldone DG. Osteoporosis, osteopenia, and inflammatory bowel disease: lessons from a real‑world study. *Pol Arch Intern Med* 2018; **128**: 411-413 [PMID: 30174323 DOI: 10.20452/pamw.4325]

9 **Lo B**, Holm JP, Vester-Andersen MK, Bendtsen F, Vind I, Burisch J. Incidence, Risk Factors and Evaluation of Osteoporosis in Patients With Inflammatory Bowel Disease: A Danish Population-Based Inception Cohort With 10 Years of Follow-Up. *J Crohns Colitis* 2020; **14**: 904-914 [PMID: 32016388 DOI: 10.1093/ecco-jcc/jjaa019]

10 **Zhou T**, Pan J, Lai B, Cen L, Jiang W, Yu C, Shen Z. Bone mineral density is negatively correlated with ulcerative colitis: a systematic review and meta-analysis. *Clin Transl Med* 2020; **9**: 18 [PMID: 32072320 DOI: 10.1186/s40169-020-00270-0]

11 **Hidalgo DF**, Boonpheng B, Phemister J, Hidalgo J, Young M. Inflammatory Bowel Disease and Risk of Osteoporotic Fractures: A Meta-Analysis. *Cureus* 2019; **11**: e5810 [PMID: 31720198 DOI: 10.7759/cureus.5810]

12 **Agrawal M**, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M. Bone, inflammation, and inflammatory bowel disease. *Curr Osteoporos Rep* 2011; **9**: 251-257 [PMID: 21935582 DOI: 10.1007/s11914-011-0077-9]

13 **Hwang SW**. Can vitamin D supplementation help control inflammation in inflammatory bowel disease beyond its classical role in bone health? *Intest Res* 2019; **17**: 157-159 [PMID: 31060197 DOI: 10.5217/ir.2019.00038]

14 **Narayanan SA**, Metzger CE, Bloomfield SA, Zawieja DC. Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by irisin treatment in chronic inflammatory bowel disease. *FASEB J* 2018; **32**: 4848-4861 [PMID: 29596023 DOI: 10.1096/fj.201800178R]

15 **Holgersen K**, Dobie R, Farquharson C, vanʼt Hof R, Ahmed SF, Hansen AK, Holm TL. Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice. *Inflamm Bowel Dis* 2015; **21**: 257-266 [PMID: 25569742 DOI: 10.1097/MIB.0000000000000269]

16 **Pietschmann P**, Mechtcheriakova D, Meshcheryakova A, Föger-Samwald U, Ellinger I. Immunology of Osteoporosis: A Mini-Review. *Gerontology* 2016; **62**: 128-137 [PMID: 26088283 DOI: 10.1159/000431091]

17 **Kenkre JS**, Bassett J. The bone remodelling cycle. *Ann Clin Biochem* 2018; **55**: 308-327 [PMID: 29368538 DOI: 10.1177/0004563218759371]

18 **Zhao Y**, Wang HL, Li TT, Yang F, Tzeng CM. Baicalin Ameliorates Dexamethasone-Induced Osteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway. *Drug Des Devel Ther* 2020; **14**: 195-206 [PMID: 32021104 DOI: 10.2147/DDDT.S225516]

19 **Stanisławowski M**, Wiśniewski P, Guzek M, Wierzbicki PM, Adrych K, Smoczyński M, Sworczak K, Celiński K, Kmieć Z. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis. *J Crohns Colitis* 2014; **8**: 802-810 [PMID: 24439762 DOI: 10.1016/j.crohns.2013.12.021]

20 **Krela-Kaźmierczak I**, Wysocka E, Szymczak A, Eder P, Michalak M, Łykowska-Szuber L, Stawczyk-Eder K, Klimczak K, Linke K, Horst-Sikorska W. Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn's disease. *Prz Gastroenterol* 2016; **11**: 30-34 [PMID: 27110308 DOI: 10.5114/pg.2015.52589]

21 **Metzger CE**, Narayanan SA, Elizondo JP, Carter AM, Zawieja DC, Hogan HA, Bloomfield SA. DSS-induced colitis produces inflammation-induced bone loss while irisin treatment mitigates the inflammatory state in both gut and bone. *Sci Rep* 2019; **9**: 15144 [PMID: 31641205 DOI: 10.1038/s41598-019-51550-w]

22 **Romano M**, Vitaglione P, Sellitto S, D'Argenio G. Nutraceuticals for protection and healing of gastrointestinal mucosa. *Curr Med Chem* 2012; **19**: 109-117 [PMID: 22300083 DOI: 10.2174/092986712803414042]

23 **Zhang Y**, Chen Q, Dai Y, Zhang Z, Tang Z. Effects of Jianpi Qingchang Bushen Prescription on Apoptosis of Osteoclasts. *Chin J Inf Tradit Chin Med* 2021; **28**: 52-56 [DOI: 10.19879/j.cnki.1005-5304.202007475]

24 **Ge L**, Cheng K, Han J. A Network Pharmacology Approach for Uncovering the Osteogenic Mechanisms of *Psoralea corylifolia* Linn. *Evid Based Complement Alternat Med* 2019; **2019**: 2160175 [PMID: 31781261 DOI: 10.1155/2019/2160175]

25 **Zhang X**, Zhao W, Wang Y, Lu J, Chen X. The Chemical Constituents and Bioactivities of Psoralea corylifolia Linn.: A Review. *Am J Chin Med* 2016; **44:** 35-60 [PMID: 26916913 DOI: 10.1142/S0192415X16500038]

26 **Zhang Q**, Zheng Y, Hu X, Hu X, Lv W, Lv D, Chen J, Wu M, Song Q, Shentu J. Ethnopharmacological uses, phytochemistry, biological activities, and therapeutic applications of Alpinia oxyphylla Miquel: A review. *J Ethnopharmacol* 2018; **224:** 149-168 [PMID: 29738847 DOI: 10.1016/j.jep.2018.05.002]

27 **Lee YM**, Son E, Kim SH, Kim DS. Effect of Alpinia oxyphylla extract *in vitro* and in a monosodium iodoacetate-induced osteoarthritis rat model. *Phytomedicine* 2019; **65**: 153095 [PMID: 31568919 DOI: 10.1016/j.phymed.2019.153095]

28 **Koh SJ**, Kim JW, Kim BG, Lee KL, Chun J, Kim JS. Fexofenadine regulates nuclear factor-κB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates acute and chronic colitis in mice. *J Pharmacol Exp Ther* 2015; **352**: 455-461 [PMID: 25538104 DOI: 10.1124/jpet.114.217844]

29 **Chaudhary G**, Mahajan UB, Goyal SN, Ojha S, Patil CR, Subramanya SB. Protective effect of *Lagerstroemia speciosa* against dextran sulfate sodium induced ulcerative colitis in C57BL/6 mice. *Am J Transl Res* 2017; **9**: 1792-1800 [PMID: 28469784]

30 **Sands BE**. Biomarkers of Inflammation in Inflammatory Bowel Disease. *Gastroenterology* 2015; **149**: 1275-1285.e2 [PMID: 26166315 DOI: 10.1053/j.gastro.2015.07.003]

31 **Even Dar R**, Mazor Y, Karban A, Ish-Shalom S, Segal E. Risk Factors for Low Bone Density in Inflammatory Bowel Disease: Use of Glucocorticoids, Low Body Mass Index, and Smoking. *Dig Dis* 2019; **37**: 284-290 [PMID: 30799399 DOI: 10.1159/000496935]

32 **Szafors P**, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, Lukas C. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. *Osteoporos Int* 2018; **29**: 2389-2397 [PMID: 29909470 DOI: 10.1007/s00198-018-4586-6]

33 **Sgambato D**, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E, Miranda A, De Mauro D, Romano L, Iolascon G, Romano M. Bone alterations in inflammatory bowel diseases. *World J Clin Cases* 2019; **7**: 1908-1925 [PMID: 31423424 DOI: 10.12998/wjcc.v7.i15.1908]

34 **Mirza F**, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. *Eur J Endocrinol* 2015; **173**: R131-R151 [PMID: 25971649 DOI: 10.1530/EJE-15-0118]

35 **Sylvester FA**. Inflammatory Bowel Disease: Effects on Bone and Mechanisms. *Adv Exp Med Biol* 2017; **1033**: 133-150 [PMID: 29101654 DOI: 10.1007/978-3-319-66653-2\_7]

36 **Schüle S**, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. Prediction of low bone mineral density in patients with inflammatory bowel diseases. *United European Gastroenterol J* 2016; **4**: 669-676 [PMID: 27733909 DOI: 10.1177/2050640616658224]

37 **Keubler LM**, Buettner M, Häger C, Bleich A. A Multihit Model: Colitis Lessons from the Interleukin-10-deficient Mouse. *Inflamm Bowel Dis* 2015; **21**: 1967-1975 [PMID: 26164667 DOI: 10.1097/MIB.0000000000000468]

38 **Maharshak N**, Packey CD, Ellermann M, Manick S, Siddle JP, Huh EY, Plevy S, Sartor RB, Carroll IM. Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation. *Gut Microbes* 2013; **4**: 316-324 [PMID: 23822920 DOI: 10.4161/gmic.25486]

39 **Jones-Hall YL**, Grisham MB. Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease. *Pathophysiology* 2014; **21**: 267-288 [PMID: 24935242 DOI: 10.1016/j.pathophys.2014.05.002]

40 **Xie M**, Zhang H, Wang W, Sherman HL, Minter LM, Cai Z, Zhang G. Triclocarban Exposure Exaggerates Spontaneous Colonic Inflammation in Il-10-/- Mice. *Toxicol Sci* 2020; **174**: 92-99 [PMID: 31868902 DOI: 10.1093/toxsci/kfz248]

41 **Argollo M**, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. *Lancet Gastroenterol Hepatol* 2019; **4:** 643-654 [PMID: 31171484 DOI: 10.1016/S2468-1253(19)30173-6]

42 **Chedid VG**, Kane SV. Bone Health in Patients With Inflammatory Bowel Diseases. *J Clin Densitom* 2020; **23**: 182-189 [PMID: 31375349 DOI: 10.1016/j.jocd.2019.07.009]

43 **Wehbeh A**, Phatharacharukul P, Fayad NF. Improvement of Osteoporosis Screening among Inflammatory Bowel Disease Patients at Gastroenterology Fellows' Clinics. *Adv Prev Med* 2020; **2020**: 7128932 [PMID: 32637177 DOI: 10.1155/2020/7128932]

44 **Luo JS**, Zhao X, Yang Y. Effects of emodin on inflammatory bowel disease-related osteoporosis. *Biosci Rep* 2020; **40** [PMID: 31934719 DOI: 10.1042/bsr20192317]

45 **Sakellariou GT**, Moschos J, Berberidis C, Mpoumponaris A, Kadis S, Molyvas E, Kouklakis G. Bone density in young males with recently diagnosed inflammatory bowel disease. *Joint Bone Spine* 2006; **73**: 725-728 [PMID: 17126059 DOI: 10.1016/j.jbspin.2006.01.017]

46 **Briot K**, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. *Osteoporos Int* 2017; **28**: 3301-3314 [PMID: 28916915 DOI: 10.1007/s00198-017-4189-7]

47 **Irwin R**, Raehtz S, Parameswaran N, McCabe LR. Intestinal inflammation without weight loss decreases bone density and growth. *Am J Physiol Regul Integr Comp Physiol* 2016; **311**: R1149-R1157 [PMID: 27733383 DOI: 10.1152/ajpregu.00051.2016]

48 **Mundy GR**. Osteoporosis and inflammation. *Nutr Rev* 2007; **65**: S147-S151 [PMID: 18240539 DOI: 10.1111/j.1753-4887.2007.tb00353.x]

49 **Glasnović A**, O'Mara N, Kovačić N, Grčević D, Gajović S. RANK/RANKL/OPG Signaling in the Brain: A Systematic Review of the Literature. *Front Neurol* 2020; **11**: 590480 [PMID: 33329338 DOI: 10.3389/fneur.2020.590480]

50 **Braz-Silva PH**, Bergamini ML, Mardegan AP, De Rosa CS, Hasseus B, Jonasson P. Inflammatory profile of chronic apical periodontitis: a literature review. *Acta Odontol Scand* 2019; **77**: 173-180 [PMID: 30585523 DOI: 10.1080/00016357.2018.1521005]

51 **Bozkurt HS**, Quigley EM. The probiotic *Bifidobacterium* in the management of Coronavirus: A theoretical basis. *Int J Immunopathol Pharmacol* 2020; **34**: 2058738420961304 [PMID: 33103512 DOI: 10.1177/2058738420961304]

52 **Bozkurt HS**, Kara B. A new treatment for ulcerative colitis: Intracolonic Bifidobacterium and xyloglucan application. *Eur J Inflammation* 2020; **18:** 1-7 [DOI: 10.1177/2058739220942626]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Animal Ethics Committee of the Shanghai University of Traditional Chinese Medicine, No. PZSHUTCM191108004.

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest related to this study.

**Data sharing statement:** The datasets generated during and/or analyzed during the current study will be available upon request from the principle investigator. The shared data will only be allowed to be used by the applicant for scientiﬁc studies. No commercial activities are allowed.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 20, 2021

**First decision:** January 9, 2022

**Article in press:** February 27, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C, C, C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Bozkurt HS, Turkey; Gassler N, Germany; Iizuka M, Japan; Romano M, Italy; Ulasoglu C, Turkey **S-Editor:** Fan JR **L-Editor:** Wang TQ **P-Editor:** Yuan YY


**Figure Legends**




**Figure 1 Gene detection results in F6-generation mice.** A: Interleukin (IL)-10 conditional knockout; B: IL-10 knockout; C: Dppa3-cre.




**Figure 2 Animal experimental flow and fecal occult blood test.** A: An experimental bone loss inflammatory bowel disease model was induced by peroral administration of piroxicam for 10 d in interleukin-10-/- mice. Normal saline or Jianpi Qingchang Bushen decoction (JQBD; 16.5 g/kg/d) was given intragastrically to the control/model groups and JQBD group, respectively (*n* = 6, each); B: Fecal occult blood test of control and model groups: The control group was negative, and the model group was strongly positive for occult blood. JQBD: Jianpi Qingchang Bushen decoction Group.




**Figure 3 General condition of the mice.** A: Disease activity index scores gauged daily (*n* = 6 *per* group); B: Body weight measured daily (*n* = 6 *per* group); C and D: Colon length measurement and graph presenting the statistical analysis results. Data are presented as the mean ± SD. a*P* < 0.05; b*P* < 0.01; c*P* < 0.001 (*n* = 6 *per* group).




**Figure 4 Histological evaluation of the colonic mucosa following hematoxylin and eosin staining (× 100) and ultrastructure of the colonic epithelium by transmission electron microscopy (× 6000).** Arrows indicate goblet cells (a), crypts (b), inﬂammatory cells inﬁltration (c), epithelium surface erosion (d), and submucosal oedema (e). Control: Control group; Model: Model group; JQBD: Jianpi Qingchang Bushen decoction Group; Nu: Nucleus; Mi: Mitochondrial; ER: Endoplasmic Reticulum; rER: Rough endoplasmic reticulum; Mv: Microvillus.




**Figure 5 Three-dimensional reconstruction of the lumbar spine trabecular structure in mice and micro-computed tomographic analyses of the lumbar vertebral metaphysis.** Bone volume to total volume (BV/TV) ratio, Conn-Dens, trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and bone mineral density (BMD) were obtained for all mice. A: Control; B: Model; C: JQBD; D: BV/TV; E: Conn-Dens; F: Trabecular number; G: Trabecular thickness; H: Trabecular separation; I: Bone mineral density. Control: Control group; Model: Model group; JQBD: Jianpi Qingchang Bushen decoction Group; BV/TV: Bone volume to total volume ratio; Conn-Dens: Connectivity-density; Tb.N: Trabecular number; Tb.Th: Trabecular thickness; Tb.Sp: Trabecular separation; BMD: Bone mineral density. Data are presented as the mean ± SD. a*P* < 0.05. (*n* = 6 *per* group).



**Figure 6 Effect of Jianpi Qingchang Bushen decoction on nuclear factor-kappaB, tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-8 gene expression.** The relative expression of these genes was quantified by real-time fluorescence quantitative polymerase chain reaction. A: NF-κB; B: TNF-α; C: IL-1β; D: IL-6; E: IL-8. Control: Control group; Model: Model group; JQBD: Jianpi Qingchang Bushen decoction Group; NF-κB: Nuclear factor-kappaB; TNF-α: Tumor necrosis factor-α; IL: Interleukin. Data are presented as the mean ± SD. a*P* < 0.05; b*P* < 0.01; c*P* < 0.001 (*n* = 3 *per* group).



**Figure 7 Effect of Jianpi Qingchang Bushen decoction on receptor activator of nuclear factor κB ligand, osteoprotegerin, receptor activator of nuclear factor kappa B, and nuclear factor-kappaB protein expression.** A: Protein expression quantified by Western blot; B: RANKL; C: OPG; D: RANK; E: NF-κB. Control: Control group; Model: Model group; RANK: Receptor activator of nuclear factor kappa B; RANKL: Receptor activator of nuclear factor κB ligand; JQBD: Jianpi Qingchang Bushen decoction Group. Data are presented as the mean ± SD. a*P* < 0.05; b*P* < 0.01; c*P* < 0.001 (*n* = 3 *per* group).



**Figure 8 Possible mechanisms of bone loss in inflammatory bowel disease.** IBD: Inflammatory bowel disease; OPG: Osteoprotegerin; RANK: Receptor activator of nuclear factor kappa B; RANKL: Receptor activator of nuclear factor κB ligand; JQBD: Jianpi Qingchang Bushen decoction Group.

**Table 1 Calculation of disease activity index score**

|  |  |  |  |
| --- | --- | --- | --- |
| **Score** | **Weight loss** | **Stool consistency** | **Bleeding** |
| 0 | Normal | Normal (well-formed pellets) | Not observed |
| 1 | 1%-5% | Normal (well-formed pellets) | Not observed |
| 2 | 6%-10% | Loose (pasty stools that do not stick to the anus) | Occult |
| 3 | 11%-15% | Loose (pasty stools that do not stick to the anus) | Occult |
| 4 | > 15% | Diarrhea (liquid stools that stick to the anus) | Gross bleeding |

**Table 2 List of primers used in this study**

|  |  |  |
| --- | --- | --- |
| **Gene** | **Primers(5’-3’)** | **Primer length** |
| NF-κB | Forward GTGGAGGCATGTTCGGTAGTG | 195 |
| Reverse TCTTGGCACAATCTTTAGGGC |  |
| TNF-α | Forward CCCTCCAGAAAAGACACCATG | 183 |
| Reverse CACCCCGAAGTTCAGTAGACAG |  |
| IL-1β | Forward GCTTCAGGCAGGCAGTATCA | 196 |
| Reverse TGCAGTTGTCTAATGGGAACG |  |
| IL-6 | Forward AAATGATGGATGCTACCAAACTG | 137 |
| Reverse CTCTGGCTTTGTCTTTCTTGTTATC |  |
| IL-8 | Forward TAGTGTTGAGCATGAAAAGCCTC | 152 |
| Reverse TGACTTCACTGGAGTCCCGTAG |  |

NF-κB: Nuclear factor-kappaB; TNF-α: Tumor necrosis factor-α; IL: Interleukin.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**